SPL
BBIO icon

Superior Planning, LLC’s BridgeBio Pharma BBIO Stock Holding History

Superior Planning, LLC’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.67K Buy
+71
New +$5.53K ﹤0.01% 1224

Other funds holding BBIO

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aisling Capital Management
Aisling Capital Management New York $299M AUM 39.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Superior Planning, LLC's BBIO Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in BridgeBio Pharma (BBIO) in Q3 2026: 71 shares worth $4.67K. The stake represents ﹤0.01% of the portfolio and ranks #1224 among its holdings.

290 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

  • Superior Planning, LLC held 71 shares of BridgeBio Pharma worth $4.67K as of Q3 2026.
  • BridgeBio Pharma was a new Superior Planning, LLC position in Q3 2026.
  • BridgeBio Pharma made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1224 holding.
  • 290 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.